Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Lantern Pharma, BMS, Cellares, Walgreens, Getlabs

NEW YORK – Lantern Pharma said this week that it was cleared by health authorities to expand its Phase II Harmonic trial evaluating its tyrosine kinases inhibitor LP-300 plus chemotherapy in biomarker-selected non-small cell lung cancer in never-smokers into both Japan and Taiwan. The trial will include patients whose tumors harbor driver mutations like EGFR, ALK, ROS1, and MET. Lantern began the Harmonic trial in the US in 2022. 

Bristol Myers Squibb and Cellares said this week that they have inked a CAR T-cell manufacturing and supply agreement. Under the terms of the agreement, BMS will pay Cellares up to $380 million in upfront and milestone payments in exchange for the chance to use Cellares' Cell Shuttle and Cell Q platforms to manufacture certain cell therapies in the US, the EU, and Japan. The deal, which is meant to bring BMS's cell therapies to more patients with a faster turnaround time, expands an existing agreement between BMS and Cellares inked in 2023. 

Walgreens this week announced the Walgreens Specialty Pharmacy unit as a component of its pharmacy business that will partner with payors and drug manufacturers, specifically focusing on services for patients with complex and chronic conditions. A key part of the business unit is an 18,000-square-foot gene and cell services pharmacy and innovation center in Pittsburgh for managing supply chain, logistics, financing, and clinical and social needs of patients in need of these therapeutics. 

At-home sample collection firm Getlabs said this week that it will provide sample collection services for genetic testing company Inocras (formerly Genome Insight), specifically for the firm's whole-genome sequencing diagnostic tests CancerVision and RareVision. 

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on Precision Medicine Online.